What are Low molecular weight heparin (LMWH) drugs?

Low molecular weight heparin (LMWH) drugs are pharmacologic agents that share a common mechanism (typically targeting Factor Xa and thrombin). 3 are currently marketed, with 4 more in clinical development.

What are the marketed Low molecular weight heparin (LMWH) drugs?

Marketed Low molecular weight heparin (LMWH) drugs include Fragmin, Lovenox (Preservative Free), half amount low molecular weight heparin.

Low molecular weight heparin (LMWH)

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3 marketed 4 in Phase 3

This page covers all Low molecular weight heparin (LMWH) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Factor Xa and thrombin, Antithrombin-III, Antithrombin III (indirect target); Factor Xa and Factor IIa (downstream targets).

Targets

Factor Xa and thrombin · Antithrombin-III · Antithrombin III (indirect target); Factor Xa and Factor IIa (downstream targets) · Antithrombin III · Antithrombin · Coagulation factors (IIa and Xa) · Factor Xa, Thrombin · Factor Xa and thrombin (via antithrombin III enhancement)

Marketed (3)

Fragmin · Pfizer Inc. · Oncology
Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin.
Lovenox (Preservative Free) · Sanofi · Cardiovascular
Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting.
half amount low molecular weight heparin · Beijing Anzhen Hospital · Cardiovascular
Low molecular weight heparin at reduced dosage inhibits blood coagulation by potentiating antithrombin III activity against factors Xa and IIa.

Phase 3 pipeline (4)

UFH · VarmX B.V. · Cardiovascular
UFH acts as an anticoagulant by inhibiting the coagulation cascade, specifically by inactivating Factor Xa and thrombin.
intermediate dose Enoxaparin/ unfractionated heparin · Rajaie Cardiovascular Medical and Research Center · Cardiovascular
Enoxaparin and unfractionated heparin work by inhibiting the coagulation cascade, specifically by activating antithrombin and inhibiting thrombin and factor Xa.
Tinzaparin Injectable Solution · Queen Mary University of London · Cardiovascular
Tinzaparin is a low molecular weight heparin that works by inhibiting coagulation factors to prevent blood clot formation.
Tinzaparin (Leo) · Aalborg University Hospital · Cardiovascular
Tinzaparin is a low molecular weight heparin that acts as an anticoagulant by inhibiting factor Xa and thrombin.

Patent intelligence

low molecular weight heparin patent landscape — aggregated cliff calendar, attackable patents, originator estates